ClinicaliQ Trial Snapshot
- TT-702 in Patients With Advanced Solid Tumours. — Recruiting • Phase I • Oncology • NCT05272709.
- What is being tested: TT-702 is a novel drug candidate undergoing evaluation for safety, tolerability, and optimal dosing in patients with advanced solid tumours, both as monotherapy and in combination regimens.
- Patient eligibility overview: The trial includes patients diagnosed with advanced solid tumours who meet specified inclusion criteria; eligibility typically requires adequate organ function and performance status, with exclusions for certain prior treatments or contraindicated conditions.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in combination with other anti-cancer agents.
Eligibility Snapshot
- : 1. Be able to provide informed consent and be capable of co-operating with IMP administration, procedures and follow-up. 2. Be willing to provide samples (blood and tissue) as required. 3. Consent to access any available archival tissue. 4. Consent for fresh tumour biopsy samples at baseline and on trial (may be Investigator mandated for patients in the dose escalation phase. Investigators will consider whether a biopsy is feasible for the patient in the dose escalation phase and this will not impede participation in the trial if biopsy is not a suitable option. 5. Life expectancy estimated by the Investigator to be at least 12 weeks. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 7. Aged 16 years or over at the time consent is given. 8. Haematological and biochemical indices within the protocol specified ranges. 9. Objectively or measurable evaluable disease, radiologically according to RECIST Version 1.1 (and/or, in mCRPC patients, according to PCWG3 criteria). Has radiological disease progression (and/or, in mCRPC patients, PSA progression according to PCWG3 criteria) at the time of trial enrolment. 10. Castrate levels of testosterone (15 mutations/MB sequenced). Non-MMRd tumours: mCRPC: - Prior treatment with a next generation hormonal agent. -…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.